Clinical Trials Logo
  1. Home
  2. Fulminant Hepatic Failure
  3. NCT00896025

Study of N-Acetylcysteine in Acute Liver Failure (ALF) — ONAC  

Acute Liver Failure Clinical Trial

Official title:
A Multi-Center Trial to Study Acute Liver Failure: N-Acetylcysteine (NAC) Open Label Use Study

Clinical Trial Summary

This proposed study is a multi-center open label study to determine if N-acetylcysteine has any survival benefits in patients with acute liver failure.

Clinical Trial Description

Patients admitted to study sites with carefully defined criteria for acute liver failure and who are thought not to have acetaminophen toxicity, mushroom poisoning, pregnancy-related liver failure, or malignancy will be eligible. Each patient will receive intravenously in solution of 5% dextrose in water containing N-acetylcysteine, beginning at a dose of 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour, and in declining doses over a total of 72 hours. Care of patients and consideration of transplantation or other clinical decisions will not be affected by the study or the use of study drug. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00896025
Study type Interventional
Source University of Texas Southwestern Medical Center
Contact
Status Terminated
Phase Phase 4
Start date December 2008
Completion date March 2016
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05491135 - Hepatocyte Microbeads for Acute Liver Failure Phase 1/Phase 2
Terminated NCT01937130 - Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF Phase 2
Withdrawn NCT05940610 - The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure Phase 1/Phase 2
Terminated NCT01875874 - Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF) Phase 2
Not yet recruiting NCT01435421 - Breath Test for Patients With Acute Liver Disease for Early Detection of the Need for Transplant or Recovery N/A
Completed NCT00245310 - Indocyangreen Elimination in Cirrhosis and Acute Liver Failure N/A
Withdrawn NCT03629015 - Safety Study of Stemchymal® in Acute Liver Failure Phase 1
Recruiting NCT04621812 - Role of Fecal Microbiota in Predicting Graft Rejection and Sepsis Among Recipients of Living Donor Liver Transplant in First Year.
Active, not recruiting NCT02833064 - Biomarkers in Liver Failure
Not yet recruiting NCT06285253 - miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial Phase 1
Recruiting NCT03882346 - Study to Evaluate Safety and Efficacy of LifeLiver in Acute or Acute-on-Chronic Liver Failure Patients Phase 2
Recruiting NCT05689645 - F573 for Injection for the Treatment of Liver Injury/Failure Phase 2
Not yet recruiting NCT05772585 - Characterization of Metabolomic Fingerprints in Patients With Acute Liver Failure and Acute-on-chronic Liver Failure With Hepatic Encephalopathy
Completed NCT00655304 - The Effect of Prometheus (R) Liver Support Dialysis on Cerebral Metabolism in Acute Liver Failure N/A
Completed NCT00059267 - Prevention of Recurrent Hepatitis B After Liver Transplantation N/A
Active, not recruiting NCT05413083 - Evaluation of Cardiac Function in Acutely Decompensated Cirrhosis
Recruiting NCT05146336 - CytOSorb TreatMent Of Critically Ill PatientS Registry
Withdrawn NCT04089969 - Cardiac Risk Assessment Using Standard of Care Versus CTA and Heart Flow FFRct N/A
Completed NCT02460510 - Role of Hypertonic Saline Versus Mannitol in the Management of Raised Intracranial Pressure in Patients With ALF N/A
Completed NCT01872767 - Spectrum, Profile and Outcome of Infections in Patients With Cirrhosis and/ or Acute on Chronic Liver Failure N/A